QbD Group
    点播网络研讨会

    Getting an Oncology IVD to Market Faster

    What Founders Underestimate Early On

    Watch the on-demand recording: Egbert Smit (CEO of MLA Diagnostics) and Annelies Rotthier (QbD Group) unpack the clinical evidence decisions that trip up oncology diagnostic startups — and how to get them right the first time.

    随时观看
    60 分钟
    Clinical
    中文

    Contents

    Chapters

    1. 00:00Welcome
    2. 06:08Introduction
    3. 19:18Early decisions that lock your path
    4. 31:46Clinical evidence strategy
    5. 47:50Key take-aways
    6. 52:00Q&A
    Experts in IVD Clinical Performance Studies

    Run Your IVD Performance Studies Successfully

    Do you need compliant clinical evidence for your IVD device? Our IVD experts are happy to support you in your IVD Performance Evaluation Studies.


    In oncology IVD, the decisions you make earliest often cost you the most later. Intended use assumptions, sample strategy, study endpoints, these choices quietly shape your regulatory path, your timeline, and your credibility with investors.

    Yet most founders only discover this when they're already locked in.

    In this 60-minute session, Egbert Smit, CEO of MLA Diagnostics, and Annelies Rotthier from QbD Group unpack the clinical evidence decisions that trip up oncology diagnostic startups, and how to get them right the first time. Egbert brings the founder's perspective from building a melanoma risk stratification diagnostic. Annelies brings the strategic lens on study design and IVDR readiness.

    No generic CRO talk. Just the early-stage thinking that separates fast, credible paths to market from expensive detours.

    您将学到什么

    • Why clinical evidence decisions made in the first months can lock you into the wrong regulatory path
    • How to design a study when your samples are limited, expensive, and irreplaceable
    • Where founders most often misalign intended use, performance claims, and study endpoints
    • What a first-time-right clinical evidence strategy looks like under IVDR — and why it matters to investors too

    继续观看

    更多 Webinars